无锡祥生医疗科技股份有限公司 募集资金管理办法 第一章 总则 第一条 为加强、规范无锡祥生医疗科技股份有限公司(以下简称"公司")募集 资金的管理, 提高募集资金使用效率和效益, 根据《中华人民共和国公 司法》《中华人民共和国证券法》《上市公司证券发行注册管理办法》 《上市公司募集资金监管规则》 《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》《上海证券交易所科创板股票上市规 则》(以下简称"《上市规则》")等法律法规和规范性文件以及《无锡 祥生医疗科技股份有限公司章程》(以下简称"《公司章程》")的规定, 结合公司实际情况, 特制定本办法。 公司的董事、高级管理人员应当勤勉尽责, 确保公司募集资金安全, 不 得操控公司擅自或变相改变募集资金用途。 第五条 公司的控股股东、实际控制人及其他关联人不得占用公司募集资金, 不得利用公司募集资金投资项目(以下简称"募投项目")获取不正当利 益。 公司发现控股股东、实际控制人及其他关联人占用募集资金的, 应当 及时要求归还, 并披露占用发生的原因、对公司的影响、清偿整改方案 及整改进展情况。 第二章 募集资金存储 第七条 公司应当在募集资金到账后一 ...

因股东自身资金需求及资金规划，公司股东无锡祥鹏投资企业(有限合伙)拟自减持计划公告披露之日起 15个交易日后的3个月内，通过集中竞价的方式减持合计不超过所持公司股份336,000股,即不超过公司总 股本的0.30%。 | | 股东名称 | 持有数量(股) | 持有比例 | 一致行动关系形成原因 | | --- | --- | --- | --- | --- | | | 无锡祥鼎投资企业(有 | 4.704.000 | 4.20% | 莫善珏、莫若理和陆坚 | | | 限合伙) | | | 为公司实际控制人,该 | | | | | | 减持主体受实际控制人 | | | | | | 陆坚控制 | | | 上海御德科技有限公 | 1.679.956 | 1.50% | 莫善压、莫若理和陆坚 | | | 司 | | | 为公司实际控制人,该 | | 第一组 | | | | 减持主体受实际控制人 | | | | | | 陆坚控制 | | 股东名称 | 无锡祥鼎投资企业(有限合伙) | | --- | --- | | 计划减持数量 | 不超过:1,176,000 股 | | 计划减持比例 | 不超过:1.05% | | ...

Core Insights - The company reported a revenue of 236 million yuan in the first half of 2025, a year-on-year decrease of 4.61%, and a net profit attributable to shareholders of 69.696 million yuan, down 14.32% year-on-year [1] - The company focuses on the research and innovation of ultrasound medical imaging equipment, aiming to become a global leader in high-end ultrasound medical imaging devices and services [1] - The company has integrated AI technology into its SonoAI platform, enhancing its SonoFamily product line with capabilities such as lesion intelligent recognition and image self-optimization [1] Product Development - The company has expanded its cardiac ultrasound solutions with high-resolution imaging, precise hemodynamic analysis, and intelligent cardiac function assessment, addressing diverse needs in the cardiac ultrasound field [2] - The company has made significant progress with its "breast AI ultrasound robot," which features an integrated design for large-scale scanning and data tracking management, supporting a full-cycle service model from screening to treatment [2] Market Expansion - The company has launched the SonoVet series for veterinary ultrasound, which combines AI and 5G remote diagnostic technology, catering to various environments such as farms and pet hospitals [3] - A recent policy from the National Medical Products Administration supports the innovation of high-end medical devices, which is expected to provide significant market opportunities for companies focusing on AI and high-end medical imaging [3] - The company aims to enhance its competitiveness in the ultrasound medical imaging field through innovation-driven strategies and international expansion [3]

Group 1 - On August 29, seven companies listed on the Sci-Tech Innovation Board announced share reduction plans, with an estimated total reduction of approximately 2.647 billion yuan based on the closing price on August 28 [1] - The reduction plans involve various stakeholders, including controlling shareholders, employee stock ownership plans, and shareholders holding more than 5% of the shares, utilizing methods such as centralized bidding, block trading, and inquiry transfer [1] - Aojie Technology announced that its shareholder, Alibaba Network, plans to reduce its holdings by up to 12.549 million shares, accounting for no more than 3% of the company's total share capital, through block trading and centralized bidding within three months after the announcement [1] Group 2 - As of the announcement date, Alibaba Network directly holds 64.5574 million shares of Aojie Technology, representing 15.4333% of the company's total share capital, with these shares originating from the company's initial public offering prior to the listing [1]

Core Insights - Xiangsheng Medical reported a revenue of 236 million yuan and a net profit of 70 million yuan for the first half of 2025, with a non-recurring net profit of 64 million yuan [1] R&D Investment and Innovation - The company emphasizes high investment in R&D, with expenses amounting to 37.61 million yuan, representing 15.93% of total revenue, highlighting its commitment to innovation [2] - In the first half of 2025, Xiangsheng Medical obtained 13 new patent authorizations, including 7 invention patents, and filed 12 new intellectual property applications, with 5 being invention patent applications [2] - The total number of invention patents held by the company reached 158, including 11 valid international patents, indicating a deepening technological moat [2] - The company expanded its core technology matrix to 63 items, adding 2 new core technologies, and enhanced its "imaging + AI" dual-driven advantage [2] Product Development and AI Integration - Xiangsheng Medical developed core technologies such as "visual recognition and analysis" and "robotic motion precision control," integrating AI-assisted screening systems to launch the "AI + robotic scanning" series for mass screening of malignant tumors [3] - The "breast AI ultrasound robot" received a medical device testing report, establishing a full-cycle management system from screening to referral and treatment [3] - The integrated design of the technology includes a touchscreen, electric examination bed, six-degree-of-freedom robotic arm, automatic ultrasound image transmission, and AI-assisted reading, facilitating large-scale screening and data tracking management [3] Global Market Expansion - In the first half of 2025, Xiangsheng Medical accelerated its international product registration, obtaining 43 new foreign market access licenses, thereby expanding its overseas market share [4] - The company’s entire series of digital color ultrasound diagnostic products passed the EU Medical Device Regulation (MDR) certification in July 2025 [4] - Xiangsheng Medical participated in over 70 global industry events and academic conferences to enhance brand exposure and clinical value [4] - The company hosted the "SonoGlobal2025" global agent conference in Dubai, Mexico, and Shanghai, launching the "Evergreen Elite Project" to upgrade core partners from "product sales" to "solution delivery" [4] Future Outlook - Xiangsheng Medical showcased its SonoFamily and SonoAI solutions at major events in Brazil, emphasizing the competitive edge of its ultra-thin, highly integrated ultrasound devices with 5G remote consultation capabilities [5] - The company aims to deepen its presence in the Brazilian market and accelerate global expansion, leveraging innovative technology to enhance local cooperation and improve regional diagnostic efficiency [5] - Looking ahead, Xiangsheng Medical plans to strengthen collaboration with global ultrasound experts to explore clinical needs and accelerate the integration of technological innovation with practical applications [5]

格隆汇8月28日丨祥生医疗(688358.SH)发布中报，2025上半年实现营业总收入2.36亿元，同比下降 4.61%；归属母公司股东净利润6969.63万元，同比下降14.32%；基本每股收益为0.62元。 ...

每经AI快讯，祥生医疗（SH 688358，收盘价：32.12元）8月28日晚间发布公告称，公司第三届第十三 次董事会会议于2025年8月28日以现场结合通讯表决方式召开。会议审议了《关于公司2025年"提质增 效"行动方案的半年度评估报告的议案》等文件。 每经头条（nbdtoutiao）——申请超2万份，已开出41家，加盟海底捞，你要准备多少钱？1000万元不算 多，真实"账单"公布 2024年1至12月份，祥生医疗的营业收入构成为：医疗器械行业占比99.88%，其他业务占比0.12%。 （记者 王可然） 截至发稿，祥生医疗市值为36亿元。 ...

截至发稿，祥生医疗市值为36亿元。 每经AI快讯，祥生医疗（SH 688358，收盘价：32.12元）8月28日晚间发布半年度业绩报告称，2025年 上半年营业收入约2.36亿元，同比减少4.61%；归属于上市公司股东的净利润约6970万元，同比减少 14.32%；基本每股收益0.62元，同比减少15.07%。 每经头条（nbdtoutiao）——申请超2万份，已开出41家，加盟海底捞，你要准备多少钱？1000万元不算 多，真实"账单"公布 （记者 王晓波） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 ...

关于取消监事会、修订《公司章程》并办理工商变更 证券代码：688358 证券简称：祥生医疗 公告编号：2025-022 无锡祥生医疗科技股份有限公司 登记及修订、废止、制定部分内部治理制度的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 无锡祥生医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 28 日召 开第三届董事会第十三次会议，审议通过了《关于取消监事会、修订<公司章程> 并办理工商变更登记的议案》《关于修订、废止、制定部分内部治理制度的议案》， 上述议案尚需公司 2025 年第一次临时股东大会审议。具体情况如下： 一、取消监事会的情况 根据《中华人民共和国公司法（2023 年修订）》（以下简称"《公司法》"）、 中国证监会《关于新<公司法>配套制度规则实施相关过渡期安排》《上市公司章 程指引（2025 年修订）》等有关规定并结合公司实际情况，公司将不再设置监事 会和监事，监事会职权由董事会审计委员会行使。公司《监事会议事规则》等与 监事或监事会有关的内部制度相应废止，同时对《无锡祥生医疗科技股份 ...

证券代码：688358 证券简称：祥生医疗 公告编号：2025-021 无锡祥生医疗科技股份有限公司 2025 年半年度募集资金存放与使用情况专项报告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 (一) 实际募集资金金额、资金到账时间 经中国证券监督管理委员会《关于同意无锡祥生医疗科技股份有限公司首次 公开发行股票注册的批复》（证监许可[2019]2018 号）核准，无锡祥生医疗科技 股份有限公司（以下简称"公司"）于 2019 年 11 月向社会公开发行人民币普通股 （A 股）20,000,000 股，每股发行价格为人民币 50.53 元，募集资金总额为人民 币 1,010,600,000.00 元 ， 扣 除 发 行 费 用 后 实 际 募 集 资 金 净 额 为 人 民 币 919,494,358.32 元。该募集资金已于 2019 年 11 月 27 日到位。上述资金到位情况 业经容诚会计师事务所（特殊普通合伙）会验字[2019]8172 号《验资报告》验证。 公司对募集资金采取了专户存储管 ...